Autologous mesenchymal stem cells (MSCs) may be a good alternative to antibody-based induction therapy in patients receiving living-related renal transplants, say researchers. Tan et al. randomized 159 patients receiving an ABO-compatible kidney transplant from a living related donor to receive autologous MSCs with standard-dose or low-dose calcineurin inhibitors (CNIs), or anti-IL-2-receptor antibodies with standard-dose CNIs. Autologous MSC use was associated with a reduced incidence of acute rejection, improved estimated renal function at 12 months, and a decreased risk of opportunistic infections.
ORIGINAL RESEARCH PAPER
Tan, J. et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 307, 1169–1177 (2012)
Rights and permissions
About this article
Cite this article
Autologous MSCs in living-related renal transplantation. Nat Rev Nephrol 8, 253 (2012). https://doi.org/10.1038/nrneph.2012.52
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.52